InMed Pharmaceuticals (INM) investor reports 4.2% beneficial stake in 137,634 shares

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. has a significant shareholder disclosure from Ikarian Capital, LLC and Neil Shahrestani. They jointly report beneficial ownership of 137,634 Common Shares of InMed Pharmaceuticals Inc., representing 4.2% of the Common Shares outstanding.

The shares are held through Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts over which Ikarian Capital has investment discretion. The reporting persons have shared voting and dispositive power over 137,634 shares and no sole power. The 4.2% figure is based on 3,314,063 Common Shares outstanding as of May 4, 2026, as disclosed by the issuer. The reporting parties include standard disclaimers regarding the extent of their beneficial ownership and group status.

Key Figures

Beneficially owned shares: 137,634 Common Shares Ownership percentage: 4.2 % Shares outstanding: 3,314,063 Common Shares +3 more

6 metrics

Beneficially owned shares 137,634 Common Shares Common Shares of InMed Pharmaceuticals Inc. beneficially owned by the reporting persons

Ownership percentage 4.2 % Percentage of InMed Pharmaceuticals Inc. Common Shares beneficially owned by the reporting persons

Shares outstanding 3,314,063 Common Shares Shares outstanding as of May 4, 2026, used to calculate the 4.2% ownership

Shared voting power 137,634.00 shares Number of shares over which the reporting persons have shared voting power

Sole voting power 0.00 shares Number of shares over which the reporting persons have sole voting power

CUSIP 457637700 CUSIP for InMed Pharmaceuticals Inc. Common Shares, no par value

Key Terms

beneficial ownership, dispositive power, separately managed accounts, Investment Advisers Act of 1940, +1 more

5 terms

beneficial ownership financial

"may be deemed to have beneficial ownership of the securities covered by this statement"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

dispositive power financial

"Shared Dispositive Power 137,634.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

separately managed accounts financial

"the Fund, and certain separately managed accounts managed by Ikarian Capital"

A separately managed account is an investment portfolio owned by a single investor but professionally managed to that investor’s specific goals and preferences, rather than pooled with other clients’ money. It matters to investors because it offers greater customization, tax control and transparency—like hiring a personal chef instead of eating from a shared buffet—though it often requires higher minimums and can have different fee and liquidity implications.

Investment Advisers Act of 1940 regulatory

"Ikarian Capital is an investment adviser registered under the Investment Advisers Act of 1940"

A U.S. federal law that sets rules for people and firms who give investment advice, requiring them to register with regulators, be honest about conflicts, keep records, and follow basic standards of care. It matters to investors because those rules act like licensing and consumer protections — similar to having safety standards for a mechanic — helping ensure advisers act in clients’ financial interests and reducing the risk of fraud or misuse of funds.

Section 13(d) or 13(g) regulatory

"for the purposes of Section 13(d) or 13(g) of the Act or any other purpose"

FAQ

What stake in InMed Pharmaceuticals Inc. (INM) does Ikarian Capital report?

Ikarian Capital and Neil Shahrestani report beneficial ownership of 137,634 Common Shares of InMed Pharmaceuticals Inc., representing 4.2% of the company’s outstanding Common Shares based on 3,314,063 shares outstanding as of May 4, 2026.

How many InMed (INM) shares were outstanding for the 4.2% calculation?

The reported 4.2% ownership is calculated using 3,314,063 Common Shares of InMed Pharmaceuticals Inc. outstanding as of May 4, 2026, as disclosed in the company’s Form 10-Q for the quarter ended March 31, 2026.

Who actually holds the InMed (INM) shares reported by Ikarian Capital?

The 137,634 Common Shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts. Ikarian Capital has investment discretion over these accounts and may be deemed to beneficially own the securities through that role.

What voting and dispositive powers do the INM reporting persons have?

The reporting persons have 0 shares with sole voting or dispositive power and 137,634 shares with shared voting and shared dispositive power. This means voting and disposition decisions are shared over the reported Common Shares.

What is the CUSIP and class of securities reported for InMed (INM)?

The securities reported are Common Shares, no par value of InMed Pharmaceuticals Inc., with CUSIP 457637700. Ikarian Capital and Neil Shahrestani report beneficial ownership in this specific class of securities.

Do Ikarian Capital and Neil Shahrestani admit group status in InMed (INM)?

They state the filing is made jointly but include a disclaimer that nothing in the statement should be construed as an admission they are a group or beneficial owners for purposes of Section 13(d) or 13(g) or any other purpose.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 09:12 PM Accepted by SEC EDGAR 08/14/2026 - 09:12 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

InMed Pharmaceuticals Inc.

(Name of Issuer)

Common Shares, no par value

(Title of Class of Securities)

457637700

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 457637700

1

Names of Reporting Persons

Ikarian Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 137,634.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 137,634.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

137,634.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: (1) The figures in Items 6, 8, and 9 represent common shares, no par value ("Common Shares") of InMed Pharmaceuticals Inc. (the "Issuer"), held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separately managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 3,314,063 Common Shares of the Issuer outstanding as of May 4, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the U.S. Securities and Exchange Commission (the "SEC") on May 6, 2026.

SCHEDULE 13G

CUSIP Number(s): 457637700

1

Names of Reporting Persons

Neil Shahrestani

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 137,634.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 137,634.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

137,634.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

IN, HC

Comment for Type of Reporting Person: (1) The figures in Items 6, 8, and 9 represent Common Shares of the Issuer held by the Fund and certain separately managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 3,314,063 Common Shares of the Issuer outstanding as of May 4, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on May 6, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: InMed Pharmaceuticals Inc.
(b)	Address of issuer's principal executive offices: Suite 1445 - 885 W. Georgia Street, Vancouver, British Columbia, Canada
Item 2.
(a)	Name of person filing: This statement is filed jointly by and on behalf of each of Ikarian Capital, LLC, a Delaware limited liability company ("Ikarian Capital"), and Neil Shahrestani (together referred herein as the "Reporting Persons"). The Fund, and certain separately managed accounts managed by Ikarian Capital (collectively, the "Managed Accounts"), are the record owners of the securities covered by this statement. Ikarian Capital is an investment adviser registered under the Investment Advisers Act of 1940, as amended, and serves as investment manager to the Fund and as sub-adviser to the Managed Accounts, and may be deemed to have beneficial ownership of the securities covered by this statement through the investment discretion it has over the Fund and the Managed Accounts. Ikarian Capital is ultimately controlled, indirectly, by Mr. Shahrestani. Accordingly, Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by Ikarian Capital. The Fund disclaims beneficial ownership of the shares held by the Managed Accounts. The Managed Accounts disclaim beneficial ownership of the shares held by the Fund. Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement. Each Reporting Person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer or (ii) a member of any group with respect to the issuer or any securities of the issuer.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is c/o Ikarian Capital, LLC, 100 Crescent Court, Suite 1620, Dallas, Texas 75201.
(c)	Citizenship: See Item 4 on the cover page(s) hereto
(d)	Title of class of securities: Common Shares, no par value
(e)	CUSIP Number(s): 457637700
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover pages(s) hereto.
(b)	Percent of class: See Item 11 on the cover page(s) hereto.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page(s) hereto.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page(s) hereto.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page(s) hereto.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page(s) hereto.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The information set forth in Item 2(a) is incorporated by reference herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ikarian Capital, LLC

Signature:	/s/ Neil Shahrestani
Name/Title:	Neil Shahrestani, Sole Manager
Date:	08/14/2026

Neil Shahrestani

Signature:	/s/ Neil Shahrestani
Name/Title:	Neil Shahrestani
Date:	08/14/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement (filed herewith).